艾司美拉唑治疗胃溃疡患者成本效果的影响因素分析

Analysis of the Influencing Factors of the Cost Effectiveness of Esomeprazole in the Treatment of Patients with Gastric Ulcer

目的:分析艾司美拉唑治疗胃溃疡患者成本效果的影响因素。方法:回顾性分析2014年9月-2018年1月我院诊治的胃溃疡患者220例的临床病例资料,根据治疗药物的不同分为观察组120例与对照组100例,对照组给予奥美拉唑+克拉霉素+阿莫西林治疗,观察组给予艾司美拉唑+克拉霉素+阿莫西林,两组均持续治疗观察2周,对比两组治疗成本、治疗效果、不良反应的发生情况和成本效果,以及影响艾司美拉唑治疗胃溃疡患者成本效果的因素。结果:观察组与对照组患者完成治疗周期的成本费用分别为567.14±48.23元、551.49±45.61元,两组比较差异无统计学意义(P>0.05)。观察组与对照组的治疗总有效率分别为95.83%(115/120)和82.00%(82/100),观察组显著高于对照组(P<0.05)。观察组与对照组治疗期间的腹胀、便秘、恶心、口腔异味等不良反应发生率为8.33%(10/120)和11.00%(11/100),对比差异无统计学意义(P>0.05)。观察组C/E与ΔC/E值均显著低于对照组(P<0.05)。多因素logistic回归分析显示病程、溃疡直径、不良反应为影响艾司美拉唑治疗胃溃疡成本效果的主要因素(P<0.05)。结论:艾司美拉唑治疗胃溃疡患者成本效果好,且不会增加不良反应的发生,病程、溃疡直径、不良反应为影响成本效果的主要因素。

Objective: To analyze the influencing factors of cost effectiveness of esomeprazole in the treatment of gastric ulcer patients. Methods: A Retrospective analysis of the clinical data of 220 cases of gastric ulcer patients who were diagnosed and treated in our hospital from September 2014 to January 2018 was performed. According to different treatment drugs, they were divided into the observation group(120 cases) and the control group(100 cases), the control group was treated with omeprazole + clarithromycin + amoxicillin, and the observation group was given esomeprazole + clarithromycin + amoxicillin, both groups were continuously treated for 2weeks. The cost of treatment, effect of treatment, occurrence of adverse reactions and cost effects were compared between two groups,the factors affecting the cost effectiveness of esmeprazole in the treatment of gastric ulcer patients were analyzed. Results: The cost of completing the treatment cycle in the observation group and the control group were 567.14±48.23 yuan and 551.49±45.61 yuan respectively, and there was no significant difference between the two groups(P>0.05). The total effective rates of observation group and control group were 95.83%(115/120) and 82.00%(82/100) respectively, which was significantly higher in the observation group than that of the control group(P<0.05). The incidence of adverse reactions, such as constipation, abdominal distention, nausea and odorness, were 8.33%(10/120) and 11.00%(11/100) in the observation group and the control group showed no significant difference(P>0.05). The values of C/E and ΔC/E in the observation group were significantly lower than those in the control group(P<0.05). Multivariate logistic regression analysis showed that the duration of disease, ulcer diameter and adverse reactions were the main factors influencing the cost effectiveness of Esomeprazole in the treatment of gastric ulcer(P<0.05). Conclusion: The cost effect of esmeprazole in the treatment of gastric ulcer is good, and it does not increase the occurrence of adverse reactions. The main factors that affect the cost effect are the course of the disease, the diameter of the ulcer and the adverse reaction.